Nanjing Medlander Medical Technology Co. Ltd. A - Asset Resilience Ratio
Nanjing Medlander Medical Technology Co. Ltd. A (688273) has an Asset Resilience Ratio of 34.29% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2024)
This chart shows how Nanjing Medlander Medical Technology Co. Ltd. A's Asset Resilience Ratio has changed over time. See 688273 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Nanjing Medlander Medical Technology Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 688273 stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥522.25 Million | 34.29% |
| Total Liquid Assets | CN¥522.25 Million | 34.29% |
Asset Resilience Insights
- Very High Liquidity: Nanjing Medlander Medical Technology Co. Ltd. A maintains exceptional liquid asset reserves at 34.29% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Nanjing Medlander Medical Technology Co. Ltd. A Industry Peers by Asset Resilience Ratio
Compare Nanjing Medlander Medical Technology Co. Ltd. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Insulet Corporation
NASDAQ:PODD |
Medical Devices | 3.71% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 39.15% |
|
Novocure Ltd
NASDAQ:NVCR |
Medical Devices | 43.72% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
|
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A
SHG:688212 |
Medical Devices | 6.09% |
|
Epitomee Medical Ltd
TA:EPIT |
Medical Devices | 0.24% |
|
DRGEM Corporation
KQ:263690 |
Medical Devices | 1.34% |
|
Micro-X Ltd
AU:MX1 |
Medical Devices | 28.12% |
Annual Asset Resilience Ratio for Nanjing Medlander Medical Technology Co. Ltd. A (2022–2024)
The table below shows the annual Asset Resilience Ratio data for Nanjing Medlander Medical Technology Co. Ltd. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 28.02% | CN¥433.42 Million ≈ $63.42 Million |
CN¥1.55 Billion ≈ $226.32 Million |
+21.14pp |
| 2023-12-31 | 6.89% | CN¥105.65 Million ≈ $15.46 Million |
CN¥1.53 Billion ≈ $224.46 Million |
+4.24pp |
| 2022-12-31 | 2.65% | CN¥40.00 Million ≈ $5.85 Million |
CN¥1.51 Billion ≈ $221.24 Million |
-- |
About Nanjing Medlander Medical Technology Co. Ltd. A
Nanjing Medlander Medical Technology Co.,Ltd. engages in the research and development, manufacture, sale, and service of pelvic floor rehabilitation equipment and related products in China and internationally. It offers pelvic floor and obstetrics and gynecology rehabilitation, reproductive rehabilitation product, and sports rehabilitation products, as well as consumables products, such as vagina… Read more